Understanding how acute myeloid leukemia becomes resistant to treatment

Who could benefit from this research

What this research studies

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) can be challenging to treat, and sometimes existing therapies lose their effectiveness. This project aims to uncover how the body's natural defense system, known as the innate immune response, might inadvertently contribute to the growth of these blood cancers. Researchers are also investigating specific genetic changes that could prevent the body from properly regulating the production of certain white blood cells, a process that might fuel leukemia development. A key focus is on a protein called Triad1, which appears to act as a natural suppressor of leukemia. By gaining a deeper understanding of these complex biological processes, we hope to identify new strategies to combat the progression and drug resistance of these difficult blood cancers.

Why it matters

Where this research is happening

• Jesse Brown VA Medical Center
  Chicago, United States Active

Researchers

• Principal investigator: Eklund, Elizabeth Ann — Jesse Brown VA Medical Center
• Study coordinator: Eklund, Elizabeth Ann

Related research

Other NIH-funded projects on the same topics.

• Targeting the SCP4 pathway in acute myeloid leukemia (AML)

  Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.

  NIH research St. Jude Children's Research Hospital · Memphis, United States · NIH-11617813

• Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant

  This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11453101

• Targeting the protein housekeeping system in adult leukemia

  Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11452453

• Understanding how epigenetic helper proteins drive AML and how to target them

  A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11448341

• Targeting FLVCR1-enabled choline use in a aggressive AML subtype

  A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.

  NIH research Seattle Children's Hospital · Seattle, United States · NIH-11427960

• Advancing CD70-targeted CAR-NK Therapy for AML

  A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11425793

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.